Celldex Therapeutics, Inc. $CLDX Shares Purchased by Eversept Partners LP

Eversept Partners LP boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 24.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,434,725 shares of the biopharmaceutical company’s stock after acquiring an additional 280,805 shares during the quarter. Celldex Therapeutics accounts for 2.0% of Eversept Partners LP’s investment portfolio, making the stock its 13th biggest position. Eversept Partners LP owned 2.16% of Celldex Therapeutics worth $38,967,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after purchasing an additional 680 shares during the period. Millennium Management LLC raised its position in Celldex Therapeutics by 327.3% in the first quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock valued at $7,259,000 after purchasing an additional 306,330 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Celldex Therapeutics by 12.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock valued at $2,383,000 after purchasing an additional 14,979 shares during the period. Russell Investments Group Ltd. raised its position in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the period. Finally, Hsbc Holdings PLC purchased a new position in Celldex Therapeutics in the second quarter valued at about $347,000.

Analysts Set New Price Targets

Several research analysts have commented on CLDX shares. Stifel Nicolaus reissued a “buy” rating and issued a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a research report on Thursday, February 26th. Wolfe Research raised Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price objective on the stock in a research report on Monday, March 23rd. Wells Fargo & Company raised their price objective on Celldex Therapeutics from $38.00 to $54.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Barclays raised their price objective on Celldex Therapeutics from $45.00 to $48.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $42.00 price objective on shares of Celldex Therapeutics in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.30.

Celldex Therapeutics Stock Performance

Shares of NASDAQ CLDX opened at $32.93 on Thursday. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of -7.73 and a beta of 0.95. Celldex Therapeutics, Inc. has a 1 year low of $19.52 and a 1 year high of $35.79. The stock’s 50-day simple moving average is $31.96 and its 200-day simple moving average is $28.97.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.80 million. As a group, research analysts predict that Celldex Therapeutics, Inc. will post -4.36 EPS for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.